The AML Global Portal were delighted to speak to Julie Bergeron, Maisonneuve-Rosemont Hospital, Montreal, CA, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Julie Bergeron: How do Canadian patients benefit from novel agents that are now used to treat patients with AML?
Julie Bergeron discusses the options of novel agents that are available to Canadian patients with AML. She explains there is a lag in the official approval process in Canada. Julie Bergeron also explains the benefits of molecular-targetted drugs but states that there needs to be a balance between enthusiasm for a novel drug and probing for patient survival data.